A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 145 participants.
Also called NCT04074551
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 145 participants
- Registry
-
NCT04074551
-
- Other papers using this trial's data
- A Randomized, Multicenter, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of a Quadruple Combination of Amlodipine, Losartan, Rosuvastatin, and Ezetimibe in Patients with Concomitant Essential Hypertension and Dyslipidemia
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- South Korea
- Registry status
- Completed
Technical summary
Registry record NCT04074551. Randomized; double masking; primary purpose treatment. Start 2019-07-16 (actual); primary completion 2020-03-17 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia
- Condition
- Hypertension
- Condition
- Dyslipidemias
- Intervention (Drug)
- HCP1701
- Intervention (Drug)
- Losartan
- Intervention (Drug)
- Amlodipine
- Intervention (Drug)
- Rosuvastatin and Ezetimibe
- Lead sponsor
- Hanmi Pharmaceutical Company Limited
Record details
- Record id
cardio:ct-nct04074551- Content hash
ed544159cd5be02224c14201b173939b655940bd4e53cab7e19f9253f2db847a